Products
Trandolapril is commercially available in the form of film-coated tablets in combination with verapamil (Tarka). It has been approved in many countries since 1994. The monopreparation Gopten was withdrawn from the market in 2014.
Structure and properties
Trandolapril (C24H34N2O5, Mr = 430.5 g/mol) exists as a white powder that is soluble in organic solvents. It is a prodrug and is hydrolyzed in the body to the active metabolite trandolaprilat.
Effects
Trandolapril (ATC C09AA10) has antihypertensive properties and unloads the heart (preload and afterload). The effects are due to inhibition of the formation of angiotensin II from angiotensin I by inhibition of angiotensin converting enzyme (ACE). Trandolapril thus abolishes the effects of antiogensin II.
Indications
For the treatment of hypertension (essential hypertension). The fixed combination Tarka with verapamil is also approved for the treatment of hypertension.
Dosage
According to the SmPC. The drugs are usually taken once daily and independently of meals.
Contraindications
- Hypersensitivity
- Previous angioedema while taking ACE inhibitors or sartans.
- Hereditary or idiopathic angioedema
- Pregnancy and lactation
- During desensitization therapy
- Concurrent use of aliskiren in patients with diabetes mellitus or impaired renal function.
Full details of precautions and interactions can be found in the drug label.
Adverse effects
The most common possible adverse effects include weakness, drowsiness, irritable cough, low blood pressure, and headache.
